CDC vaccine advisers delay Hepatitis B schedule changes while recommending separate vaccines for measles, mumps, rubella, and ...

Merck’s executive director, operations lead, global medical affairs and outcomes research discusses how data is helping to ...

VectorY Therapeutics partners with Shape Therapeutics to advance innovative therapies for neurodegenerative diseases using ...

The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...

The Health System Owned Specialty Pharmacy Alliance (HOSP) works to reduce costs and increase availability of care for ...

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, details how products having an insufficient relative advantage, enter the market too late, or are ...

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s ...

Rob DeWig, VP of Healthcare Sales at Inmar, touches on looming DSCSA enforcement and the impact of Inmar's reconciliation tools.

Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the innovative ThecaFlex DRx system.

Our five-year plan is to continue to do what we do really well and be that scaled, large, trusted partner that can help pharma and biopharma bring their new medicines and innovations into the market.

Former CDC director Susan Monarez raises alarms about potential changes to childhood vaccine schedules, warning of increased ...

GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...